Description
Latin name srdl2929rd4prf2929rd4frdaf29rd4rd4frdaf4rdrd4rdrdf29frdf Betaserc
Release form
Tablets.
Packing
30 pcs
Pharmacological action
Betaserc – improves microcirculation.
Pharmacodynamics
Betaserc (betahistine) acts primarily on the histamine H1 and H3 receptors of the inner ear and vestibular nuclei of the central nervous system. By direct agonistic action on the H1 receptors of the vessels of the inner ear, as well as indirectly through the action on the H3 receptors, it improves microcirculation and capillary permeability, normalizes the pressure of the endolymph in the labyrinth and cochlea. However, betahistine increases blood flow in the basilar arteries. Betaserk ® also has a pronounced central effect due to the influence of the vestibular nerve nuclei on the H3 receptors. Normalizes the conductivity in neurons of the vestibular nuclei at the level of the brain stem. A clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.
Indications
vestibular dizziness
syndromes characterized by dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting
disease / Meniere’s syndrome.
Contraindications
hypersensitivity to any of the components of the drug
pheochromocytoma
peptic ulcer of the stomach and duodenum in the acute phase.
Use during pregnancy and lactation
There is insufficient data on the use of betahistine in pregnant women. The potential risk to humans is unknown. Betagistin should not be used during pregnancy unless absolutely necessary.
It is not known whether betahistine and breast milk are excreted. You should not prescribe the drug during breastfeeding. The question of the appointment of Betaserk ® mother should be taken only after comparing the benefits of breastfeeding with the potential risk to the infant.
Composition
1 tablet contains:
Active substances: betahistine dihydrochloride – 8 mg.
Excipients: microcrystalline cellulose – 80.8 mg, mannitol (E421) – 25 mg, citric acid monohydrate – 2.5 mg, colloidal silicon dioxide – 2.5 mg, talc – 6.3 mg.
Dosing and Administration
The drug is given orally with meals. The dose should be selected individually depending on the response to treatment.
For adults, the dose is 24-48 mg / day.
Dose / frequency of administration:
Betaserc ® 8 mg – 1-2 tablets 3 times a day.
Betaserc ® 16 mg – 1 / 2-1 tablets 3 times a day.
Betaserc ® 24 mg – 1 tablet 2 times a day.
16 mg tablet and 24 mg tablet can be divided into 2 equal parts. To do this, place the tablet on a hard surface with the scuff up and press on it with your thumb.
Improvement is sometimes observed only after a few weeks of treatment, and a stable therapeutic effect after several months of treatment. There is evidence that the appointment of the drug at the beginning of the disease prevents its progression and / or hearing loss in later stages.
Despite the limited clinical trial data, extensive post-registration experience suggests that dose adjustment in elderly patients is not required.
No specific clinical studies have been conducted in patients with renal and / or liver failure, but post-registration experience suggests that dose adjustment in this group of patients is not required.
Side effects of
Gastrointestinal upsets (nausea, feeling of heaviness in the epigastrium) are possible, which can be prevented by taking the drug after meals or by reducing the dose. In very rare cases, the appearance of hypersensitivity reactions from the skin, in particular, skin rash, itching and urticaria, has been reported.
Overdose
Symptoms: mild and moderate nausea, drowsiness, abdominal pain was observed in some patients after up to 640 mg. More serious complications (convulsions, cardiopulmonary complications) were observed with the intentional administration of betahistine in high doses, especially in combination with an overdose of other drugs.
Treatment: carrying out symptomatic therapy.
Storage conditions
The drug should be stored out of the reach of children, in a dry place at a temperature not exceeding 25 ° C.
Expiration
5 Chron
Deystvuyuschee substances
betahistine
dosage form
dosage form
tablets
